You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Monoclonal B Cell Lymphocytosis

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Lymphoproliferative Disorders, Premalignant, Monoclonal B-Cell Lymphocytosis Trial (No intervention)

Not yet recruiting
  • Lymphoproliferative Disorders
  • +3 more
  • No intervention
  • (no location specified)
Jan 30, 2023

Autoimmune Hemolytic Anemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial (Ibrutinib 420 mg)

Not yet recruiting
  • Autoimmune Hemolytic Anemia
  • +3 more
  • Ibrutinib 420 mg
  • (no location specified)
Jan 12, 2023

Agricultural Health Study Cohort Pesticide Exposure Study

Completed
  • Multiple Myeloma
  • +3 more
    • Iowa City, Iowa
    • +1 more
    Jan 25, 2023

    Commercially Available Vaccines Against SARS-CoV-2 in

    Recruiting
    • Monoclonal B-Cell Lymphocytosis
    • +3 more
      • Rochester, Minnesota
        Mayo Clinic
      Feb 10, 2022

      Aplastic Anemia, Hematopoietic and Lymphoid Cell Tumor, Malignant Solid Tumor Trial in Columbus (Best Practice, Ibrutinib)

      Active, not recruiting
      • Aplastic Anemia
      • +6 more
      • Columbus, Ohio
        Ohio State University Comprehensive Cancer Center
      Feb 24, 2022

      Family Study of Lymphoproliferative Disorders

      Recruiting
      • Lymphoma, Non-Hodgkin
      • +4 more
        • Rochester, Minnesota
          Mayo Clinic
        Aug 30, 2021

        Monoclonal B-Cell Lymphocytosis, Stage 0 Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia Trial in Scottsdale,

        Terminated
        Has Results
        • Monoclonal B-Cell Lymphocytosis
        • +3 more
        • Laboratory Biomarker Analysis
        • +2 more
        • Scottsdale, Arizona
        • +2 more
        Jan 15, 2021

        Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Waldenstrom Macroglobulinemia Trial in Milwaukee

        Enrolling by invitation
        • Monoclonal Gammopathy of Undetermined Significance
        • +6 more
          • Milwaukee, Wisconsin
            Aurora Health Care
          Jul 20, 2021

          Kinetics of Lymphoid Cells in Monoclonal B-cell Lymphocytosis,

          Completed
          • Lymphoma, Mantle-cell
          • +4 more
            • Bethesda, Maryland
              National Institutes of Health Clinical Center, 9000 Rockville Pi
            Jul 13, 2020

            Study on the Diagnosis and Management of CLL in Italy by GIMEMA

            Recruiting
            • Chronic Lymphocytic Leukemia
            • +2 more
              • Alessandria, Italy
              • +17 more
              Jan 3, 2022

              Recurrent DLBCL, Recurrent Follicular Lymphoma, Refractory DLBCL Trial in Seattle (Laboratory Biomarker Analysis, Pembrolizumab,

              Active, not recruiting
              • Recurrent Diffuse Large B-Cell Lymphoma
              • +3 more
              • Laboratory Biomarker Analysis
              • +3 more
              • Seattle, Washington
                Fred Hutch/University of Washington Cancer Consortium
              Jul 20, 2022

              B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory Trial in China (Orelabrutinib, Recombinant humanized mAb MIL62 injection)

              Active, not recruiting
              • B-cell Lymphoma Recurrent
              • B-cell Lymphoma Refractory
              • Orelabrutinib
              • Recombinant humanized monoclonal antibody MIL62 injection
              • Bengbu, Anhui, China
              • +9 more
              Nov 11, 2022

              B-cell Non-Hodgkins Lymphoma (B-NHL) Trial (Odronextamab, REGN5837)

              Not yet recruiting
              • B-cell Non-Hodgkins Lymphoma (B-NHL)
              • (no location specified)
              Jan 5, 2023

              Aggressive Non-Hodgkin Lymphoma, ALK-Positive Large B-Cell Lymphoma, B-Cell Lymphoma, Unclassifiable, With Features Intermediate

              Recruiting
              • Aggressive Non-Hodgkin Lymphoma
              • +8 more
              • Polatuzumab Vedotin
              • +6 more
              • Seattle, Washington
                Fred Hutch/University of Washington Cancer Consortium
              Jan 26, 2023

              Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Classic Hodgkin Lymphoma, Recurrent

              Not yet recruiting
              • Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma
              • +21 more
              • Biopsy
              • +8 more
              • Columbus, Ohio
                Ohio State University Comprehensive Cancer Center
              Apr 7, 2023

              Recurrent DLBCL, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma Trial in Duarte (Biopsy,

              Not yet recruiting
              • Recurrent Diffuse Large B-Cell Lymphoma
              • +11 more
              • Biopsy
              • +5 more
              • Duarte, California
                City of Hope Medical Center
              Jan 3, 2023

              Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6

              Not yet recruiting
              • Grade 3b Follicular Lymphoma
              • +5 more
              • Biospecimen Collection
              • +9 more
              • (no location specified)
              Jun 6, 2023

              Recurrent DLBCL, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma Trial in Houston (other, drug,

              Recruiting
              • Recurrent Diffuse Large B-Cell Lymphoma
              • +3 more
              • Laboratory Biomarker Analysis
              • +3 more
              • Houston, Texas
                M D Anderson Cancer Center
              Jul 26, 2022

              Recurrent DLBCL, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory DLBCL Trial in United States (drug, other, biological)

              Active, not recruiting
              • Recurrent Diffuse Large B-Cell Lymphoma
              • +5 more
              • Duarte, California
              • +3 more
              Nov 17, 2022

              Recurrent DLBCL, Recurrent High Grade B-Cell Lymphoma, Recurrent Transformed B-Cell Non-Hodgkin Lymphoma Trial in United States

              Active, not recruiting
              • Recurrent Diffuse Large B-Cell Lymphoma
              • +5 more
              • Mogamulizumab
              • Pembrolizumab
              • Sacramento, California
              • +7 more
              Sep 15, 2022

              Non-Malignant Tumor Trial in Seattle (biological, drug, radiation, procedure)

              Recruiting
              • Non-Malignant Neoplasm
              • Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10
              • +7 more
              • Seattle, Washington
                Fred Hutch/University of Washington Cancer Consortium
              Aug 29, 2022

              Aggressive B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular

              Recruiting
              • Aggressive B-Cell Non-Hodgkin Lymphoma
              • +19 more
              • CD47 Antagonist ALX148
              • +2 more
              • Houston, Texas
                M D Anderson Cancer Center
              Aug 9, 2022

              DLBCL, Not Otherwise Specified, High Grade B-Cell Lymphoma, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to DLBCL Trial

              Not yet recruiting
              • Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
              • +2 more
              • Biospecimen Collection
              • +5 more
              • (no location specified)
              Sep 5, 2023

              Double-Expressor Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma

              Not yet recruiting
              • Double-Expressor Lymphoma
              • +3 more
              • Sacramento, California
                University of California Davis Comprehensive Cancer Center
              Oct 27, 2022

              Aggressive Non-Hodgkin Lymphoma, Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Ann Arbor Stage II

              Active, not recruiting
              • Aggressive Non-Hodgkin Lymphoma
              • +13 more
              • Columbus, Ohio
                Ohio State University Comprehensive Cancer Center
              Aug 18, 2022